$
0.000
-5.84(-100.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
37.88M
EV
154.31M
EV/OCF(TTM)
--
P/S(TTM)
0.53
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
FY2025Q1
100.47M
+3.67%
--
--
102.14M
-1.94%
--
--
92.23M
-9.49%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Nevro Corp. (NVRO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by %.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
9 Analyst Rating
up Image0
Wall Street analysts forecast NVRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVRO is 5.85 USD with a low forecast of 5.85 USD and a high forecast of 5.85  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
9 Hold
0 Sell
Hold
up Image0
Current: 0
sliders
Low
5.85
Averages
5.85
High
5.85
Canaccord Genuity
William Plovanic
Hold
Maintains
$4 → $5.85
2025-02-07
Reason
Piper Sandler
Adam Maeder
Sell
to
Hold
Upgrades
$6 → $5.85
2025-02-07
Reason
Truist Securities
Richard Newitter
Hold
Maintains
$7 → $4.7
2024-12-18
Reason
Wells Fargo
Nathan Treybeck
Hold
Maintains
$5 → $4
2024-12-11
Reason
Wells Fargo resumed coverage of Nevro with an Equal Weight rating and $5 price target. Wells believes Nevro is comfortable with consensus implying a return to year over year sales growth in the second half of 2025, though the firm does not see upside to Street estimates, the analyst tells investors in a research note. Easier y/y comps, lessened competitive trialing, AdaptivAI ramp, continued healthy growth in painful diabetic neuropathy, adding new sales territories, and Vyrsa ramping could support 2025 growth, the firm says.
Citigroup
Joanne Wuensch
Hold
Maintains
$6 → $5
2024-12-11
Reason
Citi analyst Joanne Wuensch lowered the firm's price target on Nevro to $5 from $6 and keeps a Neutral rating on the shares as part of a 2025 outlook for the U.S. medical technology sector. The stocks that outperformed in 2024 followed the traditional med tech path, and Citi expects the same in 2025: launching differentiated products that can be leveraged to the bottom-line, with management teams providing consistent delivery, the analyst tells investors in a research note. Citi names Boston Scientific (BSX) and Insulet (PODD) its top picks for 2025.
Canaccord Genuity
William Plovanic
Hold
Maintains
$7 → $4
2024-12-09
Reason
Canaccord lowered the firm's price target on Nevro to $4 from $7 and keeps a Hold rating on the shares. Canaccord said they are bullish on the Med-Tech sector heading into 2025 as they expect investor interest to increase given smid-cap valuations continue to remain depressed while M&A has picked up and the IPO market seems to have opened. They highlight how AI is changing the space and are seeing continued interest in value-based care in the US, and believe that med-tech is well positioned to help drive the trend for improving patient outcomes while also reducing overall costs.

Valuation Metrics

The current forward P/E ratio for Nevro Corp (NVRO.N) is -2.30, compared to its 5-year average forward P/E of -28.10. For a more detailed relative valuation and DCF analysis to assess Nevro Corp 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-28.10
Current PE
-2.30
Overvalued PE
-1.05
Undervalued PE
-55.15

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-31.57
Current EV/EBITDA
-12.91
Overvalued EV/EBITDA
282.52
Undervalued EV/EBITDA
-345.67

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
5.23
Current PS
0.53
Overvalued PS
9.96
Undervalued PS
0.51

Financials

Annual
Quarterly
FY2024Q3
YoY :
-6.69%
96.91M
Total Revenue
FY2024Q3
YoY :
-40.64%
-15.17M
Operating Profit
FY2024Q3
YoY :
-34.65%
-15.34M
Net Income after Tax
FY2024Q3
YoY :
-36.92%
-0.41
EPS - Diluted
FY2024Q3
YoY :
-102.01%
161.00K
Free Cash Flow
FY2024Q3
YoY :
-1.52%
65.91
Gross Profit Margin - %
FY2024Q3
YoY :
-21.13%
-13.51
FCF Margin - %
FY2024Q3
YoY :
-29.99%
-15.83
Net Margin - %
FY2024Q3
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

NVRO News & Events

Events Timeline

2025-04-22 (ET)
2025-04-22
08:30:04
Thirteen option delistings on April 22nd
select
2025-04-03 (ET)
2025-04-03
08:47:08
Globus Medical completes acquisition of Nevro
select
2025-03-04 (ET)
2025-03-04
16:18:24
Nevro is not issuing FY25 guidance
select
Sign Up For More Events

News

7.0
03-23Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, NVRO, PLYA on Behalf of Shareholders
9.5
03-04PRnewswire
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results
3.0
03-02NASDAQ.COM
NEVRO Earnings Preview: Recent $NVRO Insider Trading, Hedge Fund Activity, and More
Sign Up For More News

FAQ

arrow icon

What is Nevro Corp (NVRO) stock price today?

The current price of NVRO is 0 USD — it has increased 0 % in the last trading day.

arrow icon

What is Nevro Corp (NVRO)'s business?

arrow icon

What is the price predicton of NVRO Stock?

arrow icon

What is Nevro Corp (NVRO)'s revenue for the last quarter?

arrow icon

What is Nevro Corp (NVRO)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Nevro Corp (NVRO)'s fundamentals?

arrow icon

How many employees does Nevro Corp (NVRO). have?

arrow icon

What is Nevro Corp (NVRO) market cap?